177Lu-PP-F11N

177Lu-PP-F11N is a radiopharmaceutical composed of the synthetic peptide PP-F11N, a gastrin analog that binds specifically to the cholecystokinin 2 (CCK2) receptor, conjugated to the beta-emitting radioisotope lutetium Lu 177. Upon intravenous administration, the peptide targets and binds CCK2 receptors, which are overexpressed in more than 90% of medullary thyroid carcinomas (MTC). The attached radioactive isotope delivers cytotoxic beta radiation directly to tumor cells expressing CCK2R, enabling both targeted therapy and imaging (theranostics). This agent is under investigation primarily for advanced or metastatic MTC and has also been studied in well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs), lung NETs, and thymic NETs. The drug demonstrates favorable biodistribution with low kidney and bone marrow radiation doses; however, stomach uptake may be dose-limiting due to physiological CCK2R expression[2][3][5][6][7][10].

Other names

Lutetium Lu 177 PP-F11N